You're Losing Weight on Semaglutide

You're Losing Weight on Semaglutide. You May Also Be Losing the One Thing That Determines Whether It Lasts.

The medication is working. The scale moves every week. Appetite is down. The food that used to consume your thoughts is quieter. For the first time in years, the body feels manageable.

And somewhere in the clinical literature, a problem is accumulating that nobody has explained to you.

Why This Is Happening to You

Semaglutide treats obesity as the neurobiological condition it is. Dismissing it as cheating is equivalent to dismissing blood pressure medication for people who could theoretically just relax more. Obesity has a genetic and neurological architecture. Semaglutide addresses that architecture.

The problem is not the medication. The problem is what happens to muscle while the medication works. In the STEP 1 trial published in New England Journal of Medicine (Wilding et al., 2021), participants lost an average of 15.3kg over 68 weeks. Approximately 45% of that weight was lean mass. A follow-up study in Diabetes, Obesity and Metabolism (Wilding et al., 2022) found that within one year of stopping semaglutide, two-thirds of the weight lost had returned — and cardiometabolic improvements reverted toward baseline.

The weight comes back because muscle was lost. Muscle is the primary driver of resting metabolic rate. When the medication stops and appetite returns, there is less metabolic capacity to absorb it.

Why Standard Fitness Advice Fails Semaglutide Users

Generic fat-loss programs push caloric restriction without addressing the protein targets or resistance training volumes needed to preserve lean mass. Generic muscle-building programs assume a functioning appetite. Semaglutide suppresses the hunger signals that would otherwise prompt the protein intake required to rebuild muscle after training.

Research in New England Journal of Medicine (Lundgren et al., 2021) found that combining exercise with GLP-1 therapy doubled fat loss compared with either intervention alone — and only the exercise-containing arms preserved lean mass. The first eight to twelve weeks on semaglutide represent a recomposition window. Most users do not know it is open.

What You Actually Need

You need resistance training tracked against body composition, not just scale weight. You need protein targets that account for suppressed appetite — high enough to protect lean mass even when eating less feels sufficient. You need to see how your composition is shifting week over week before you stop the medication.

The Tool That Was Missing

GloFlow is not a fitness app. It is a body intelligence platform, and for people using GLP-1 medications, it is the difference between a transformation that holds and one that reverses.

The Digital Twin shows you your body at three, six, and twelve months, built from your actual data and updated every time your goals or your measurements change. It shows you what is happening to your composition — not just your weight — as the medication does its work.

The Correlation Engine watches the relationship between your nutrition, your measurements, (and soon your workout volume and your PRs), and surfaces the patterns specific to your body. When protein intake drops below what your lean mass requires, you see it in the data before you feel it in the mirror.

The window is open. GloFlow helps you use it.

Download GloFlow on the App Store.

GloFlow is a fitness tracking app, not a medical tool. Consult your healthcare provider for medical advice.